PJ view: Treatments for COVID-19 - where are we now?
Pharmaceutical Journal
; 306(7950), 2022.
Article
in English
| EMBASE | ID: covidwho-2064964
article; clinical practice; clinical trial (topic); community acquired pneumonia; coronavirus disease 2019/dt [Drug Therapy]; coronavirus disease 2019/pc [Prevention]; coronavirus disease 2019/th [Therapy]; drug industry; evaluation study; human; intensive care; long COVID; lung ventilation; mortality; oxygen therapy; pandemic; practice guideline; prophylaxis; risk reduction; treatment planning; amodiaquine/dt [Drug Therapy]; antivirus agent/dt [Drug Therapy]; ciclesonide/dt [Drug Therapy]; colchicine/dt [Drug Therapy]; convalescent plasma/dt [Drug Therapy]; corticosteroid/dt [Drug Therapy]; dexamethasone/dt [Drug Therapy]; hydroxychloroquine/dt [Drug Therapy]; ivermectin/dt [Drug Therapy]; nirmatrelvir plus ritonavir/dt [Drug Therapy]; nitazoxanide/dt [Drug Therapy]; remdesivir/dt [Drug Therapy]; sarilumab/dt [Drug Therapy]; SARS-CoV-2 vaccine/dt [Drug Therapy]; tocilizumab/dt [Drug Therapy]
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
Pharmaceutical Journal
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS